According to the Zhixin Finance App, on August 16, the Hang Seng Company announced the latest quarterly review results. Simcere Pharmaceutical Group (01244) was removed from the Hang Seng Composite Mid-Cap Index. The change will be implemented after the market closes on September 6, 2024 (Friday) and will take effect on September 9, 2024 (Monday). China International Capital Corporation (CICC) research report pointed out that Simcere Pharmaceutical Group may be removed from the Hong Kong Stock Connect due to reasons such as market cap decline, lack of liquidity, or violation of relevant regulations. It is worth noting that the company's stock price hit a new low for the year on July 30 and has fallen nearly 50% this year.

As of December 31, 2023, the company has established a pipeline composed of 12 drugs or candidate drugs. Among them, Envafolimab (envolimab, subcutaneous injection of PD-L1) has been approved and commercialized in mainland China and Macau. In 2023, Envafolimab's sales revenue was RMB 0.635 billion, a year-on-year increase of 11.9%. As the only commercialized product of the company, this part of the revenue happens to be the company's total revenue for the whole year. From the perspective of performance fundamentals, it seems difficult for the company to regain investors' confidence with only one commercialized product.